News Releases

Global Fund Board Welcomes Final Eighth Replenishment Outcome of US$12.64 Billion, Backs Strategic Shifts to Advance Countries’ Path to Self-Reliance

18 February 2026

GENEVA – The Board of the Global Fund to Fight AIDS, Tuberculosis and Malaria (the Global Fund) welcomed the final outcome of the partnership’s Eighth Replenishment – US$12.64 billion – at its 54th meeting on 12-13 February.

“This remarkable result, achieved in a challenging global context, reflects the strong support for the Global Fund’s lifesaving mission and its unique partnership model,” said Peter Sands, Executive Director of the Global Fund. “We are deeply grateful to our co-hosts, South Africa and the United Kingdom, our donors, and the entire partnership for their tireless support.”

The Board hailed the broad engagement across the partnership in mobilizing resources, highlighting the leadership of South Africa and the United Kingdom as co-hosts of the Eighth Replenishment, the driving force of civil society and communities, and the growing contribution of the private sector. At the same time, the Board underscored that funding gaps threaten progress toward ending the three diseases and noted that efforts to mobilize additional resources will continue.

Based on the final outcome of US$12.64 billion in total pledges, the Board approved US$10.78 billion in allocations to countries for the 2027-2029 implementation period, complemented by US$260 million for catalytic investments. (Decision Points [ download in English ]). 

These catalytic investments are designed to accelerate progress in priority areas, such as expanding access to innovative health products through market shaping and strengthening regional manufacturing capacities, thereby amplifying the impact of country grants. An additional US$306 million in private sector funding has been earmarked for catalytic investments. Private sector resource mobilization efforts are ongoing and are expected to further increase the total funding available for catalytic investments.

Strategic Shifts 

Given the resource-constrained environment and significant changes in global health financing, the Board agreed that grant funding will be allocated in accordance with the key strategic shifts introduced by the Global Fund at the end of 2025 to focus resources toward the poorest countries with the heaviest disease burdens and support countries in accelerating on their path to self-reliance as they work toward ending the three diseases. 

“Supporting countries to transition away from Global Fund support is not new; what is new is the scale and pace of transition we are now driving,” said Sands. “We will work with countries to reinforce sustainability and accelerate their journey to self-reliance – supporting, incentivizing and, ultimately, getting out of the way. That means tailored transition pathways for every country, backed by stronger national systems, new sources of finance, and sustained access to affordable, quality-assured health products. To navigate this new reality, we have designed the strategic shifts needed to ensure transitions that are responsible and rooted in national contexts and priorities.” 

The strategic shifts will guide countries in the next grant cycle, with:

• Greater prioritization of the least-resourced and highest‑burden countries.
• Defined, predictable transition timelines tailored to national contexts, disease burden and economic conditions.
• Optimized use of all available resources through rigorous programmatic prioritization, increased co-financing, market shaping, reinforced integration into national health systems, and community systems financing.

“It’s our duty to steer the partnership through this period of uncertainty in a way that protects sustainability, preserves impact and ensures that the Global Fund continues to deliver for the people and communities we serve,” said Lady Roslyn Morauta, Chair of the Global Fund Board. “The decisions on country allocations and catalytic investments – together with the key strategic shifts in how we operate – provide a financial foundation to the new grant cycle.” 

“As we look ahead to countries’ journeys toward self‑reliance, the people most affected and most vulnerable must stay at the center of everything we do,” said Global Fund Board Vice-Chair Bience Gawanas. “Strong community systems and community‑led responses are fundamental to sustainability, and the Board’s strong backing for efforts to safeguard these systems during transition periods reflects that shared conviction.”

Innovation and Transformation 

Executive Director Peter Sands aligned with the Board in outlining priorities for 2026 and beyond. He stressed the need to maximize the impact of every dollar by accelerating equitable access to game-changing biomedical innovations – highlighting, among others, the continued scale-up of the HIV prevention tool lenacapavir as a top priority, as well as the rollout of innovative near-point-of-care molecular diagnostics for tuberculosis, and faster access to alternative first-line treatments and new vector control tools for malaria, such as spatial emanators.

In response to current political and economic realities, Sands reaffirmed – with the Board’s support – the Global Fund’s commitment to continue to transform though implementation of the strategic shifts, and to play a proactive and constructive role in shaping a global health ecosystem that is more collaborative, more coherent and more responsive to country and community priorities, drawing on the strengths of its model – particularly its strong leverage in market shaping, pooled procurement, and civil society- and community‑led interventions.

The Board concluded with a session on ongoing leadership selection processes. The next Board Chair and Board Vice-Chair will be appointed in mid-2026 and each will serve a three‑year term from October 2026 to 2029. The Board will select the Global Fund’s next Executive Director in October 2026.